Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 14/20 | 0.98 |
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.81 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.81 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.81 |
| ▸ | GLA | P06280 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.79 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9317314 | 1.00 | ADRB3 (0.98) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Bromide SCHEMBL9799484 | 1.00 | ADRB3 (0.98) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL5144153 | 0.99 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL4611391 | 0.99 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL5144149 | 0.99 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9006835 | 0.99 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL5144151 | 0.99 | ADRB3 (1.00) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| Trifluoroacetic Acid SCHEMBL9318455 | 0.93 | ADRB3 (0.89) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9812024 | 0.90 | ADRB3 (0.84) | ADRB3ADRB2ADRB1GLACYP2D6 | |
| SCHEMBL9812022 | 0.90 | ADRB3 (0.84) | ADRB3ADRB2ADRB1GLACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250346646-A1 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250282760-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12331018-B2 | Pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220411490-A1 | METHOD TO IDENTIFY COMPOUNDS USEFUL TO TREAT DYSREGULATED LIPOGENESIS, DIABETES, AND RELATED DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-12-29 | — | — | US | disclosed |
| US-20220354848-A9 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2022-11-10 | — | — | US | disclosed |
| CN-109642908-B | Compounds useful for treating metabolic disorders | 哈佛学院院长及董事 | 2022-08-16 | — | — | CN | disclosed |
| US-11401266-B2 | Process for the preparation of an orexin receptor antagonist | Merck Sharp & Dohme (UK) Ltd. (GB) | 2022-08-02 | — | — | US | disclosed |
| US-11345748-B2 | Method of treating idiopathic pulmonary fibrosis and kidney fibrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220144771-A1 | PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | ADRB3 313/4885ADRB2 372/4885ADRB1 303/4885 |
| US-20220354848-A9 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | ADRB3 2601/4885ADRB2 2300/4885ADRB1 1154/4885 |
| US-11401266-B2 | Process for the preparation of an orexin receptor antagonist | HCRTR2, HCRTR1, CRHR1 | ADRB3 354/4885ADRB2 244/4885ADRB1 235/4885 |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | ADRB3 131/4885ADRB2 177/4885ADRB1 161/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB3 273/4885ADRB2 338/4885ADRB1 142/4885 |
| US-11345748-B2 | Method of treating idiopathic pulmonary fibrosis and kidney fibrosis | CNR2, FABP1, FABP4 | ADRB3 218/4885ADRB2 106/4885ADRB1 126/4885 |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | ADRB3 392/4885ADRB2 352/4885ADRB1 316/4885 |
| US-20250282760-A1 | OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | ADRB3 264/4885ADRB2 226/4885ADRB1 186/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB3 273/4885ADRB2 338/4885ADRB1 142/4885 |
| US-12331018-B2 | Pyrrolidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | ADRB3 496/4885ADRB2 465/4885ADRB1 387/4885 |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | ADRB3 276/4885ADRB2 314/4885ADRB1 298/4885 |
| US-20220144771-A1 | PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | ADRB3 496/4885ADRB2 465/4885ADRB1 387/4885 |
| US-20220411490-A1 | METHOD TO IDENTIFY COMPOUNDS USEFUL TO TREAT DYSREGULATED LIPOGENESIS, DIABETES, AND RELATED DISORDERS | FABP4, LIPC, CNR2 | ADRB3 425/4885ADRB2 295/4885ADRB1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.